News Archives - Page 133 of 703

ThursdaySep 28, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on…

WednesdaySep 27, 2023 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, recently posted promising results from its ELPIS I clinical trial. Of note was data that showed that 100% of the ten patients who…

WednesdaySep 27, 2023 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Showcases Quantum’s Real-World Value Through Customer Success Stories

D-Wave is the world’s first commercial supplier of quantum computing solutions D-Wave’s customers have built quantum and quantum-hybrid applications in areas such as resource scheduling, mobility, logistics, drug discovery, portfolio optimization, manufacturing processes, and more Using D-Wave’s annealing quantum computing solutions, SavantX was able to increase deliveries per crane per day by 60% at Pier 300 at the Port of Los Angeles, one of the nation’s largest ports D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, is helping customers solve highly complex business problems today, helping to drive operational efficiencies, reduce costs, and increase revenue.…

TuesdaySep 26, 2023 11:15 am

Dawson James Small Cap Growth Conference: Exploring a Changing World of Investment Opportunities

Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Conference to be held in Wyndham Grand Harborside Jupiter, Jupiter, FL, October 12, 2023. The distinguished conference serves as a hallmark in the financial world, featuring important management experts slated to share cutting-edge innovations, strategies, and growth opportunities. The highly anticipated 8th Annual Investor Conference provides a unique platform for evolving and established small-cap growth companies within the healthcare, technology, and consumer sectors. It’s a unique opportunity for ground-breaking businesses to showcase their products and services…

TuesdaySep 26, 2023 9:45 am

Amid REE Market Supply Interruptions, Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Presses Forward With Commercial Processing Plant Plans

Ucore Rare Metals Inc. is moving forward with a rare earth element (“REE”) processing facility in Louisiana that will help to establish an American base for the REE supply chain The REE supply chain is currently almost exclusively controlled by the People’s Republic of China thanks to China’s responsibility for 36.7 percent of the world’s REE reserves, 63 percent of REE mining capacity and more than 90 percent of REE refining capacity REE price increases this month as a result of temporary production shutdowns in Myanmar and China underscore the market’s sensitivity to supply interruptions resulting from governmental policies Ucore’s…

TuesdaySep 26, 2023 9:00 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027 RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for…

MondaySep 25, 2023 11:15 am

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) Commences Diamond Drilling with Third Drill Hole at PCH Project in Brazil

The global rare earth elements market is expected to grow from 167.99 million tons in 2023, and to 206.25 million tons by 2028 – growing at a CAGR of 4.19% Since starting the project, Appia has commenced diamond drilling in addition to its current reverse circulation and auger drilling campaigns Specimens from the drilling efforts will be submitted to SGS Geosol laboratory, with assays expected two months from submission The global rare earth elements (“REE”) market is expected to grow from 167.99 million tons in 2023 to 206.25 million tons by 2028 – growing at a CAGR of 4.19%. The…

MondaySep 25, 2023 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent The company has stated that…

MondaySep 25, 2023 9:45 am

Electronic Servitor Publication Network Inc. (XESP) Helps Businesses Compete and Win Through The Increasingly Recognized Necessity of Marketing Automation

XESP, through its Digital Engagement Engine(TM), is making automation, powerful data management, and an advanced workflow, more accessible to B2B companies The company allows businesses to offer buyers meaningful and empowering experiences, making them feel appreciated and understood, and moving them to action XESP understands businesses’ concerns, especially regarding the cost of automation, and continues to refine its products, integrating new features and addressing emerging customer needs, all at a more competitive price point By integrating new features and making new offerings, the company is staying ahead of the competition and stamping its position as a leader in the digital…

Site Search

Company Search

Category: News